SCHEMBL5155056

SCHEMBL5155056

CCc1ccc(C2SCC(=O)N2CCc2cccnc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.61
ALDH1A1 P00352 3/20 0.61
POLB P06746 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
LMNA P02545 4/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
TDP1 Q9NUW8 2/20 0.55
HPGD P15428 2/20 0.54
GAA P10253 2/20 0.49
KCNA5 P22460 1/20 0.49
KDM4E B2RXH2 1/20 0.49
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
PTGS1 P23219 1/20 0.48
PTGS2 P35354 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5152195 0.83 MAPT (0.56) MAPTALDH1A1POLBNPSR1LMNA
SCHEMBL5156994 0.82 MAPT (0.56) MAPTALDH1A1POLBNPSR1LMNA
SCHEMBL5156174 0.82 CACNA1B (0.67) MAPTALDH1A1POLBNPSR1LMNA
SCHEMBL5152808 0.80 MAPT (0.53) MAPTALDH1A1POLBNPSR1LMNA
SCHEMBL5151364 0.79 MAPT (0.55) MAPTALDH1A1POLBNPSR1SMN1; SMN2
Hydrochloric Acid SCHEMBL5156372 0.79 MAPT (0.54) MAPTALDH1A1POLBNPSR1SMN1; SMN2
SCHEMBL5156746 0.77 LMNA (0.55) MAPTALDH1A1LMNASMN1; SMN2TDP1
SCHEMBL5151451 0.75 SMN1; SMN2 (0.85) MAPTALDH1A1LMNASMN1; SMN2TDP1
SCHEMBL11056912 0.74 MAPT (1.00) MAPTALDH1A1POLBNPSR1TDP1
SCHEMBL11058159 0.74 MAPT (1.00) MAPTALDH1A1POLBNPSR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed
WO-2004017965-A1 1,3-THIAZOLIN-4-ONES AS THERAPEUTIC COMPOUNDS IN THE TREATMENT OF PAIN IONIX PHARMACEUTICALS LIMITED (GB) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 MAPT 3411/4885ALDH1A1 3381/4885POLB 4811/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MAPT 2432/4885ALDH1A1 1370/4885POLB 4735/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MAPT 2432/4885ALDH1A1 1370/4885POLB 4735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.